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Abstract
Background: The association between low levels of vitamin D and the occurrence of chronic widespread pain
(CWP) remains unclear. The aim of our analysis was to determine the relationship between low vitamin D levels and
the risk of developing CWP in a population sample of middle age and elderly men.
Methods: Three thousand three hundred sixty nine men aged 40–79 were recruited from 8 European centres for a
longitudinal study of male ageing, the European Male Ageing Study. At baseline participants underwent assessment
of lifestyle, health factors, physical characteristics and gave a fasting blood sample. The occurrence of pain was
assessed at baseline and follow up (a mean of 4.3 years later) by shading painful sites on a body manikin. The
presence of CWP was determined using the ACR criteria for fibromyalgia. Serum 25-hydroxyvitamin D (25-(OH) D)
was assessed by radioimmunoassay. Logistic regression was used to determine the relationship between baseline
vitamin D levels and the new occurrence of CWP.
Results: Two thousand three hundred thirteen men, mean age 58.8 years (SD = 10.6), had complete pain and
vitamin data available and contributed to this analysis. 151 (6.5 %) developed new CWP at follow up and 577
(24.9 %) were pain free at both time points, the comparator group. After adjustment for age and centre, physical
performance and number of comorbidities, compared to those in upper quintile of 25-(OH) D ( ≥36.3 ng/mL), those in
the lowest quintile (<15.6 ng/mL) were more likely to develop CWP (Odds Ratio [OR] = 1.93; 95 % CI = 1.0-3.6). Further
adjustment for BMI (OR = 1.67; 95 % CI = 0.93-3.02) or depression (OR = 1.77; 95 % CI = 0.98-3.21), however rendered the
association non-significant.
Conclusions: Low vitamin D is linked with the new occurrence of CWP, although this may be explained by underlying
adverse health factors, particularly obesity and depression.
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Background
Musculoskeletal pain (MSP) is a leading cause of mor-
bidity and presentation to primary care [1–4]. In the
United Kingdom, 37 % of women and 31 % of men re-
port some kind of chronic pain [5] and approximately
10 % report chronic widespread pain (CWP) [3]. The
aetiology of CWP is complex and somewhat poorly
understood though both physical and psychological fac-
tors have been associated with its development [6–12].
Osteomalacia, a disorder due to profound vitamin D
deficiency, is associated with widespread musculoskel-
etal pain. It remains unclear whether less severe forms
of deficiency are also linked with musculoskeletal pain.
Vitamin D is obtained either from diet or by synthesis
in the skin following UVB light exposure. Prior to
becoming biologically active it undergoes two hydrox-
ylations, firstly to 25-hydroxyvitamin D (25-(OH) D)
and subsequently to the biologically active form, 1,25
dihydroxyvitamin D (1,25-(OH) 2D. 25-(OH) D has a
long half-life and is used as an indicator of vitamin D
status [13].
Results of observational studies assessing the relation-
ship between vitamin D and musculoskeletal pain are
somewhat inconsistent, with some, though not all,
reporting a significant association between low vitamin
D and CWP in specific groups [8, 14, 15]. Similarly in
fibromyalgia, a sub-type of CWP, some studies suggest
an association with vitamin D deficiency [16, 17] whilst
others do not [18, 19]. Using cross-sectional data from
the baseline arm of the European Male Ageing Study
(EMAS), a multicentre cohort study designed to assess
the incidence and prevalence of a range conditions asso-
ciated with male ageing, we reported an association be-
tween CWP and low vitamin D in men at baseline,
though the effect was attenuated after adjustment for
age, physical activity level, lifestyle factors and depres-
sion [15]. There are to our knowledge, however, no data
from prospective studies. Experimental studies assessing
the effects of vitamin D supplementation on patients’
chronic pain results are also conflicting: a Cochrane re-
view, incorporating trials assessing the effects of vitamin
D supplementation on participants with and without
vitamin D deficiency, found insufficient evidence of a
role for vitamin D supplementation in the treatment of
chronic pain [20]. Thus the link between low vitamin D
and CWP remains uncertain.
Using data from the prospective arm of EMAS, the
aim of this study was to determine i) whether low vita-
min D levels were associated with an increased risk of
developing CWP in those without CWP, ii) whether low
vitamin D was linked with changes in number of re-
ported painful sites and iii) whether any of the apparent




Three thousand three hundred sixty nine men were re-
cruited for participation in a population study of male age-
ing, the European Male Ageing Study (EMAS). Details of
the study have been reported previously [21]. Briefly men
aged between 40 and 79 years were recruited between
2003–2005 from local population registers across eight
European centres, Florence (Italy), Leuven (Belgium),
Lodz (Poland), Malmo (Sweden), Manchester (UK),
Santiago de Compostela (Spain), Szeged (Hungary) and
Tartu (Estonia). Stratified random sampling was used to
generate equal numbers of subjects in four 10 year age
groups, 40–49, 50–59, 60–69 and 70–79. Participants
were invited to take part by letter of invitation which in-
cluded a postal questionnaire, and an invitation to attend
a local clinic for further assessment. The number of sub-
jects recruited varied slightly by centre (range 396–451).
Those who attended completed a series of interviewer-
assisted questionnaires, had an assessment of physical
performance, height and weight and gave a fasted
blood sample. 41 % (range 24.1 %-61.5 %) of those in-
vited fully participated in the baseline study by com-
pleting both the postal questionnaire and attending the
assessment centre. Ethical approval was obtained in
each of the centres (Florence-Ethical Committee of the
Azienda Ospedaliera Careggi, Leuven-Commissie
Medische Ethiek UZ Gasthuisberg, Lodz-Bioethical
Committee of Medical University of Lodz for Human
Studies, Malmo-Ethical Committee of Lund University,
Manchester-North West Multi Centre Ethical Research
Committee, Santiago de Compostela-Comité Ético de
Investigación Clínica de Galicia, Szeged-Human Investiga-
tion Review Board, University of Szeged, Tartu-Ethical
Committee, Medical University of Tartu) in accordance
with local procedures and all participants gave written in-
formed consent.
Follow up
Participants were invited to attend for repeat assessment
after a mean interval of 4.3 years (range 3–5.7 years).
During this time there were 193 deaths. 3176 surviving
participants were invited to take part in the follow up
stage of the study and 2736 (86 %) did so. Further details
of the cohort characteristics are reported elsewhere [22].
Baseline assessment
The baseline postal questionnaire included questions about
lifestyle, including smoking and frequency of alcohol con-
sumption and outdoor exercise [21]. Participants were
asked how many days a week they consumed alcohol (re-
sponse set = never, <1, 2–3, 3–4, 5–6 and > 7 days per
week). Smoking status was assessed by were asking whether
participants had ever smoked at least 100 cigarettes or been
McCabe et al. BMC Musculoskeletal Disorders  (2016) 17:32 Page 2 of 9
a regular pipe or cigar smoker. Those answering yes to any
of the questions were considered as ever smokers. Outdoor
exercise was assessed by asking how long participants typic-
ally spent outdoors walking or cycling each day (response
set = <30 minutes, 30–60 minutes and >60 minutes).
Participants were asked to self-report in the postal
questionnaire a range of 16 comorbid conditions which
included whether they had ever been diagnosed with
cancer, told by a doctor they had a stroke and if they
were currently receiving treatment for epilepsy, hyper-
tension, chronic bronchitis, asthma, peptic ulcers, dia-
betes and heart, liver, kidney, prostate, adrenal, pituitary,
thyroid or testicular disease. They were also asked if they
had ever fractured a bone after the age of 25. At their
clinic visit participants completed an interviewer-assisted
questionnaire which included the 21-point Beck Depres-
sion Inventory [23] (with scores ≥10 coded as indicating
the presence of ‘depression’) and Physical Activity in the
Elderly (PASE) score [24]. Participants completed a 50
foot walking test and also a sit to stand test with the time
taken to complete each task recorded in seconds [25, 26].
Height and weight were also measured and body mass
index (BMI) was calculated as weight in kilograms divided
by height in metres squared.
Assessment of pain
At baseline and follow up in the postal questionnaire
participants were asked ‘In the past month have you had
any pain which has lasted for one day or more? Those
who reported experiencing pain were asked to shade
where they experienced pain on a 4 view body manne-
quin, Fig. 1. To assess chronicity they were asked
‘Thinking about this ache or pain, have you been aware
of it for more than 3 months?’ Pain was then coded to
number of pain sites using a 29-region coding frame
[27]. Three groups were defined: those experiencing no
pain, those with some pain and those with CWP. The
latter defined as those meeting the American College of
Rheumatology 1990 criteria for fibromyalgia [28]: pain
involving the axial skeleton, both sides of the body and
above and below the waist lasting for at least 3 months.
This method to assess pain has been used widely in popula-
tion studies and has construct validity [27, 29, 30]. Partici-
pants who met the criteria for CWP at follow up but not
baseline were coded as having developed new CWP.
Biochemical assays
At baseline, following an overnight fast, a blood sample
was taken and the serum was frozen at−80 °C and sent
on dry ice to a single laboratory for analysis (University
of Leuven). Serum levels of 25-(OH) D, as the recom-
mended marker of vitamin D status [31], were deter-
mined by radioimmunoassay (DiaSorin; Stillwater,
Minnesota, USA) with results expressed as ng/mL.
Intra-and inter-assay coefficients of variation (CV) for
25-(OH) D were 11 % and 8 %, respectively. The detec-
tion limit of the radioimmunoassay kit for 25-(OH) D
was 1.5 ng/ml. We also assessed the serum levels of
Fig. 1 Four view body mannequin, with imposed 29 region coding frame, on which participants were asked to shade the site of their pain
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1,25-dihydroxyvitamin D (1,25-(OH) 2D) as this is the
biologically active form of vitamin D. Serum 1, 25-
(OH) 2D levels were measured using high perform-
ance liquid chromatography-tandem mass spectrom-
etry as described by Casetta et al. [32] and modified
by Vanderschueren et al. [33] with results expressed
as pg/mL. Ultra pure methanol (Optima liquid chroma-
tography/mass spectrometry, Fisher Scientific) was used
for protein precipitation of 200 μL serum samples. 180 μl
of supernatant was injected on a Shimadzu Prominence
HPLC (Shimadzu, Kyoto, Japan) coupled to a AB Sciex
API 5500 QTRAP tandem mass spectrometer (Sciex,
Warrington, UK). The limit of quantification was
<6.25 pg/mL. The inter-day imprecision of pooled serum
at high and low serum 1,25-(OH) 2D concentrations was
assessed. For serum with a low concentration (mean
7.16 pg/mL) the CV was 10.1 % and 5.9 % for serum with
a high concentration (mean 55.8 pg/mL).
Statistical analysis
Descriptive statistics were used to describe the charac-
teristics of the study sample. Depending on their distri-
bution parametric (t-tests) and nonparametric (wilcoxon
rank sum) tests to determine the significance of any dif-
ferences in any of the continuous variables between
those who developed new CWP at follow up and those
who were pain free at both time points. χ2 tests were
used to test differences in categorical data. 25-(OH) D
and 1,25-(OH) 2D levels were categorised into quintiles.
We used logistic regression to determine the association
between the new occurrence of CWP and 25-(OH) D
and 1,25-(OH) 2D with those in the highest quintile as
the reference category. Adjustments were made for fac-
tors which significantly differed between those with new
CWP at follow up and those who remained pain free
throughout. This included age and centre and subse-
quently physical performance (time to sit from standing
and time to walk 50 feet), number of comorbidities, BMI
and the presence of depression (determined by BDI
≥10). We also assessed the relationship between vitamin
D deficiency and CWP with 25-(OH) <20 ng/mL consid-
ered to represent deficiency [13]. We looked also at the
number of painful sites (out of 29) at baseline and follow
up. Because of the large number of participants with no
painful sites (N= 962) zero-inflated negative binomial re-
gression was performed to assess the relationship be-
tween vitamin D and the numbers of pain sites reported
at follow up. Adjustments were made for age and centre
and subsequently for physical performance (time to sit
from standing and time to walk 50 feet), number of co-
morbidities, BMI and the presence of depression (deter-
mined by BDI ≥10). To limit the analysis to change in
number of pain sites over the follow up period we also
adjusted for the number of pain sites reported at
baseline. Results of the logistic regression were pre-
sented as Odds Ratios (OR) and for zero-inflated nega-
tive binomial regression as Incidence Rate Ratio (IRR);
both with 95 % confidence intervals. Statistical analysis




Two thousand seven hundred thirty six men participated
in both the baseline and follow up phases of EMAS. Of
these 2313 (84.5 % of those who participated in both
phases and 68.7 % of those in the original cohort) had
complete data for 25-(OH) D and pain at baseline and
follow up and were included in this analysis. Measure-
ment of vitamin D was undertaken during the; summer
N = 269 (11.6 %), autumn N = 816 (35.3), winter N = 701
(30.3 %) and spring N= 527 (22.8 %). The mean age of
these participants at baseline was 58.8 years (standard
deviation [SD] = 10.6 years).
Baseline characteristics
Baseline characteristics of the 2313 with complete data
are presented in Table 1. Mean BMI was 27.6 Kg/m2
[SD = 4.0]. 57.4 % of men consumed alcohol at least
once a week, 69.7 % had ever smoked and 11.8 % were
depressed. 60.9 % had at least one comorbid condition
and 41.1 % two comorbid conditions. Mean 25 (OH) D,
and 1,25 (OH) 2D levels, were 25.9 ng/mL [SD = 12.6]
and 59.4 pg/ml [SD = 15.9], respectively. 195 (8.4 %) par-
ticipants fulfilled the criteria for CWP, 1159 (50.1 %) had
some pain (pain which did not meet the CWP criteria)
and 959 (41.5 %) were pain free. The median number of
pain sites was 1 (IQR 0–4).
Pain status at follow up
Overall 223 (9.6 %) participants fulfilled the criteria for
CWP at follow up, 1140 (49.3 %) had some pain and 950
(41.1 %) reported no pain. Of the 2118 men without
CWP at baseline 151 (7.1 %) developed new onset CWP
at follow up. 577 participants (25.0 %) were pain free at
both baseline and follow up. Overall at follow up pain
status was different from baseline for 980 (42.4 %) par-
ticipants, see Table 2.
Factors linked with the new occurrence of CWP
Compared to those without pain at baseline or follow up
those who developed new onset CWP (N= 151) were more
likely to have a higher BMI (28.6 vs. 27.2 Kg/m2; p < 0.001)
and were more likely to have a BDI score of ≥10 indicating
the presence of depression (23.5 % vs. 5.6 %; p < 0.001), see
Table 3. They were also more likely to have at least 2 self-
reported comorbidities, have a longer sit to stand time
(13.3 vs. 12.2 seconds; p < 0.001) and time to walk 50 feet
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(14.2 vs. 12.9 seconds; p < 0.001). There was no signifi-
cance difference observed in their 25 (OH) D (24.2
vs. 26.3 ng/mL; P = 0.07) or 1,25 (OH) D (58.2 pg/mL
vs. 60.2 pg/mL; P = 0.21) levels. There was also no
significant difference in their PASE score, level of
self-reported outdoors activity, smoking or alcohol
consumption.
Vitamin D and CWP
After adjustment for age and centre, compared to those
in the upper quintile of 25-(OH) D (>36.3 ng/mL) those
in the lowest quintile (<15.6 ng/mL) were more likely to
develop CWP (OR = 2.32; 95 % CI = 1.27–4.23), see
Table 4. This relationship remained significant after
adjustment for physical performance and comorbid-
ity though not after further adjustment for BMI and
depression (determined by BDI ≥10), OR = 1.60,
95 % CI = 0.83-3.09. Adjustment for either BMI (OR
= 1.67; 95 % CI = 0.93-3.02) or depression (OR = 1.77;
95 % CI = 0.98–3.21), in addition to age and centre,
also rendered the relationship not statistically signifi-
cant. After adjustment for age and centre, compared to
those in the upper quintile of 1, 25 (OH) 2D, those in
lower quintiles were more likely to develop CWP though
none were statistically significant. We identified no associ-
ation between CWP and the presence of vitamin D defi-
ciency (25-(OH) D <20 ng/mL) in either the adjusted or
unadjusted analysis when compared to those with higher
levels (adjusted for age and centre, OR 1.32; 95 % CI
0.91–1.93).
Vitamin D and number of pain sites
At baseline those with CWP at follow up had median 8
(IQR 6–11) painful sites and those with some pain had 3
(IQR 2–5). After adjusting for age and centre, compared
to those in the upper quintile of vitamin D, those in the
5th and 2nd quintile were more likely to report more
pain sites (5th quintile IRR = 1.2; 95 % CI = 1.0–1.4; 2nd
quintile IRR 1.2 95 % CI 1.0–1.3), see Table 5. After ad-
justment for number of pain sites at baseline these asso-
ciations became non-significant. Further adjustment for
physical performance, comorbidity, BMI and depression
(presence determined by BDI ≥10) attenuated slightly
the IRRs. There was no significant relationship observed
between 1,25 (OH) 2D and number of pain sites.
Discussion
In this analysis, compared to those in the upper quintile
of serum 25 (OH) D level men in the lowest quintile
(<15.6 ng/mL) at baseline were more likely to have de-
veloped CWP at follow up though this appeared to be
related to the presence of adverse health factors, particu-
larly obesity and depression. No significant association
was observed between 1,25 (OH) 2D and the new occur-
rence of CWP.
Some previous observational and experimental studies
have suggested that low levels of vitamin D may have a
causal role in the development of chronic pain, though
the evidence is conflicting [20]. We however observed,
after adjustment, no independent association between
vitamin D at baseline and CWP at follow up in our male,
and largely Caucasian, population and our results are in
keeping with previous studies which have found no asso-
ciation either at all or not in men [8, 15, 18], though a
significant association has been reported previously in
women [8]. There is also some evidence of ethnic vari-
ation in the prevalence of CWP with higher rates




Age (years) 58.8 (10.6)
Body mass index (kg/m2) 27.6 (4.0)
Sit to stand time (seconds) 12.4 (3.2)
Time to walk 50 feet (seconds) 13.2 (2.8)
PASE score 201.2 (88.4)
25 (OH) D (ng/mL) 25.9 (12.6)
1,25 (OH) 2 D (pg/mL) 59.4 (15.9)
Alcohol-number of days alcohol consumed N (%)
Never 349 (15.1)





Ever smoked (vs. never smoker) 1612 (70.8)





Self-reported ≥30 minutes walking/cycling
outside per day (vs. <30 minutes)
1493 (64.8)
Pain status
Pain free 959 (41.5)
Some pain 1159 (50.1)
CWP 195 (8.4)
median (IQR)
Number of pain sites 1 (0–4)
PASE, Physical Activity Scale for the Elderly; 25 (OH) D, 25-hydroxyvitamin D3;
1,25 (OH) 2 D, 1,25-dihydroxyvitamin D3. aThe presence of depression was
determined using Beck Depression Inventory with scores ≥10 indicating the
presence of depression
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observed in non-caucasians [14, 34] and in some ethnic
groups, such as British residents of South Asian ethnic
origin the prevalence of both vitamin D deficiency and
CWP are significantly increased [14]. It is therefore pos-
sible that whilst we did not observe an independent as-
sociation between low vitamin D and the development
of CWP in our population the pathogenesis of CWP
may be different in specific groups, and in some this
may include low vitamin D.
We also assessed the association 1,25-(OH) 2D, the
biologically active form of vitamin D and CWP. We ob-
served a trend towards an increased risk of CWP for
Table 3 Subject characteristics at baseline by pain status
Subject characteristics Pain free at baseline and follow up (N = 577) New onset chronic widespread pain at follow up (N = 151)
mean (SD) mean (SD)
Age (years) 58.9 (10.7) 59.3 (10.5)
Body mass index (kg/m2) 27.2 (3.8) 28.6 (4.2)‡
Sit to stand time (seconds) 12.2 (3.0) 13.3 (4.0)‡
Time to walk 50 feet (seconds) 12.9 (2.2) 14.2 (4.7)‡
PASE score 196.0 (94.4) 194.8 (89.1)
25 (OH) D (ng/mL) 26.3 (12.2) 24.2 (12.2)
1,25 (OH) 2D (pg/mL) 60.2 (16.3) 58.2 (17.2)
Alcohol-number of days alcohol consumed N (%) N (%)
Never 82 (14.2) 34 (22.7)
<1 week 166 (28.8) 38 (25.3)
1–2 124 (21.5) 29 (19.3)
3–4 66 (11.4) 21 (14.0)
5–6 38 (6.6) 11 (7.3)
7 101 (17.5) 17 (11.3)
Ever smoked (vs. never smoker) 377 (66.6) 110 (73.3)
Depressiona (vs. not depressed) 32 (5.6) 35 (23.5)†
Number of comorbidities
None 272 (47.1) 37 (24.5)
1 108 (18.7) 25 (16.6)
≥2 197 (34.1) 89 (58.9)†
Self-reported ≥30 minutes walking/cycling
outside per day (vs. <30 minutes)
382 (66.4) 99 (65.6)
PASE, Physical Activity Scale for the Elderly; 25 (OH) D, 25-hydroxyvitamin D3; 1,25 (OH) 2 D, 1,25 dihydroxyvitamin D3. *The presence of depression was determined
using Beck Depression Inventory with scores ≥10 indicating the presence of depression. †Chi squared test p < 0.05, ‡T test p < 0.05
Table 2 Change in pain status between baseline and follow up
Pain status at follow up Total
Pain free Some pain Chronic widespread pain
Pain status at baseline Pain free 577 355 27 959
(41.5)
Some pain
351 684 124 1159
(50.1)
Chronic widespread pain
22 101 72 195
(8.4)
Total 950 1140 223 2313
(41.1) (49.3) (9.6)
All values are N (%)
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those in the lowest quintile of 1,25-(OH) 2D, though in
contrast to our findings with 25-(OH) D, even in the un-
adjusted analysis this did not reach statistical signifi-
cance. 1,25-(OH) 2D has a short half-life and the serum
level is dependent on a range of other factors including
serum phosphate, calcium and parathyroid hormone
levels. Current guidance recommends 1,25-(OH) 2D is
not useful in determining the vitamin D status of patients
[31] and therefore this measure likely poorly reflects the
vitamin D status of our population.
Approximately half of the study participants at either
baseline or follow up reported experiencing some pain,
though did not meet the criteria for CWP. This is a het-
erogeneous group ranging from those with localised pain
to those almost meeting the criteria for CWP. It seems
unlikely, however, that inclusion or reclassification of
those with more severe pain (within the ‘some pain’
group) would have influenced the findings.
In our population 8.4 % and 9.6 % of participants met
the criteria for CWP at baseline and follow up respect-
ively, which is higher than the prevalence of CWP previ-
ously reported in community-dwelling men [3, 4]. We
observed significant changes in pain status between
baseline and follow up with some 42.4 % of participants
Table 5 The association between baseline 25 (OH) D and 1,25 (OH) 2D and the number of painful sites at follow up
Model 1 Model 2 Model 3 Model 4
25 (OH) D-quintiles
1: ≥36.3 ng/mL Referent Referent Referent Referent
2: 26.7–36.2 ng/mL 1.16 (1.00–1.34)* 1.12 (0.98–1.28) 1.11 (0.97–1.26) 1.13 (0.99–1.29)
3: 20.7–26.6 ng/mL 1.05 (0.91–1.22) 1.05 (0.92–1.21) 1.03 (0.90–1.19) 1.03 (0.90–1.18)
4: 15.6–20.6 ng/mL 1.12 (0.96–1.30) 1.12 (0.98–1.29) 1.12 (0.97–1.28) 1.12 (0.97–1.28)
5: <15.6 ng/mL 1.20 (1.03–1.40)* 1.14 (0.99–1.31) 1.11 (0.97–1.28) 1.10 (0.95–1.26)
1,25 (OH) 2 D-quintiles
1: ≥72.5 pg/ml Referent Referent Referent Referent
2: 62.2–72.5 pg/mL 0.95 (0.81–1.11) 0.93 (0.81–1.07) 0.92 (0.80–1.06) 0.93 (0.81–1.07)
3: 55.2–62.0 pg/mL 0.98 (0.84–1.14) 0.99 (0.86–1.14) 0.98 (0.85–1.13) 1.00 (0.86–1.15)
4: 45.4–55.0 pg/mL 1.06 (0.91–1.23) 1.09 (0.95–1.26) 1.10 (0.96–1.27) 1.10 (0.95–1.26)
5: <45.4 pg/mL 1.03 (0.88–1.21) 1.10 (0.88–1.17) 1.04 (0.90–1.20) 1.03 (0.89–1.19)
Results determined using zero-inflated negative binomial regression with those in the highest quintile serving as the referent group. Results are expressed as Incidence
rate ratio (95 % confidence intervals) * p < 0.05. 25-(OH) D, 25-hydroxyvitamin D3; 1,25-(OH) 2D, 1,25 dihydroxyvitamin D3. Model 1, adjusted for age and centre; Model
2, adjusted for age, centre and number of pain sites at baseline; Model 3, adjusted for age, centre, and number of pain sites at baseline and physical performance (sit to
stand time and time to walk 50 feet); Model 4, adjusted for age, centre, and number of pain sites at baseline, physical performance, number of comorbidities, body mass
index and depression (the presence of depression was determined using Beck Depression Inventory with scores ≥10 indicating depression)
Table 4 The association between baseline 25 (OH) D and 1,25 (OH) 2D and the new occurrence of chronic widespread pain
Model 1 Model 2 Model 3 Model 4
25 (OH) D–quintiles
1: ≥36.3 ng/mL Referent Referent Referent Referent
2: 26.7–36.2 ng/mL 1.41 (0.76–2.59) 1.24 (0.66–2.32) 1.23 (0.64–2.33) 1.07 (0.55–2.08)
3: 20.7–26.6 ng/mL 1.43 (0.77–2.65) 1.29 (0.68–2.43) 1.30 (0.68–2.48) 1.18 (0.60–2.30)
4: 15.6–20.6 ng/mL 1.29 (0.68–2.42) 1.17 (0.61–2.23) 1.19 (0.61–2.30) 1.18 (0.60–2.31
5: <15.6 ng/mL 2.32 (1.27–4.23)* 2.03 (1.10–3.75)* 1.93 (1.03–3.62)* 1.60 (0.83–3.09)
1,25 (OH) 2 D–quintiles
1: ≥72.5 pg/ml Referent Referent Referent Referent
2: 62.2–72.5 pg/mL 1.15 (0.60–2.21) 1.05 (0.54–2.04) 0.99 (0.50–1.96) 0.94 (0.46–1.90)
3: 55.2–62.0 pg/mL 1.23 (0.65–2.34) 1.12 (0.58–2.17) 1.12 (0.57–2.20) 1.07 (0.52–2.17)
4: 45.4–55.0 pg/mL 1.37 (0.70–2.65) 1.41 (0.72–2.77) 1.42 (0.71–2.83) 1.33 (0.65–2.73)
5: <45.4 pg/mL 1.79 (0.94–3.42) 1.70 (0.87–3.31) 1.55 (0.78–3.08) 1.52 (0.74–3.11)
Results determined using logistic regression with those in the highest quintile serving as the referent group. Results are expressed as odds ratio (95 % confidence
intervals) * p < 0.05. 25 (OH) D, 25-hydroxyvitamin D3; 1,25 (OH) 2D, 1,25 dihydroxyvitamin D3. Model 1, adjusted for age and centre; Model 2, adjusted for age,
centre and physical performance (sit to stand time and time to walk 50 feet); Model 3, adjusted for age, centre, physical performance and comorbidities; Model 4,
adjusted for age, centre, physical performance, comorbidities, body mass index and depression (the presence of depression was determined using Beck Depression
Inventory with scores ≥10 indicating depression)
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changing pain status which is broadly consistent with
findings from other studies [35, 36].
We observed a strong association between depression, the
presence of which was determined using the BDI, and CWP.
This has been observed in other studies and is consistent
with reports of the NHANES-1 cohort [37] in the USA
which found depression predicted the risk of developing
chronic musculoskeletal pain. We also observed that in-
creased BMI was a predictor of CWP in keeping with the co-
occurrence of CWP and raised BMI reported previously [38],
although this is the first prospective study to demonstrate a
link. Smoking and alcohol consumption were not however
linked with CWP in contrast to previous reports [39].
There are a number of limitations which need to be
considered in interpreting our data. The participation
rate for the baseline survey was 41 % of those invited to
take part. There were significant differences between
those who participated in the full study (N = 3369) and
those who returned the initial postal questionnaire only
(N= 594), most relevant of which was the prevalence of
pain. 59.4 % of full study participants reported pain last-
ing one day or more in the preceding month at baseline
compared to 43.8 % of those who returned the question-
naire only [21]. Such potential selection factors mean
that caution is needed in interpreting the absolute preva-
lence of pain observed, however, they are unlikely to
have influenced our main findings of a link between
CWP and vitamin D which were based on an internal
comparison of those recruited. In our study pain status
was assessed prospectively after an interval of 4.3 years
following assessment of vitamin D. Any change in vita-
min D status during that time would result in misclassi-
fication of D status and reduce the likelihood of findings
significant associations. In a study though of postmeno-
pausal women there was only moderate intra-individual
variation in serum 25-(OH) D between baseline and fol-
low up at 5 years and the authors supported the use of
single point measurement of vitamin D in prospective
studies with follow up periods less than 5 years [40].
Vitamin D is synthesised in the skin, dependant on skin
type and levels of UVB exposure, however, we did not
have any information about these factors in our data,
and were not therefore able to make adjustment for
them. There is also variation in levels of D during the
year with higher levels during the summer months–we
observed however no association between CWP and sea-
son (data not shown) and so did not make any adjust-
ment for season. It is also possible that any effect of
vitamin D on the development of CWP occurs through
a mediator variable, such as depression [41], which we
treated as a confounder and adjusted for in our analysis
thereby potentially masking a true association. Addition-
ally, physical activity and performance was assessed
using the PASE score, time to stand from sitting and
also time to walk 50 feet. Though widely used, these
tests have not been validated across the entire age range
included in this study. Finally the men who contributed
data to this analysis were predominantly European and
Caucasian and the results should be extrapolated be-
yond this with caution.
Conclusions
In this population study men with very low vitamin D
(25-(OH) D <15.6 ng/mL) at baseline were at signifi-
cantly increased risk of having developed CWP at follow
up, though this appears to be related to other adverse
health factors, particularly raised BMI and depression.
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